# Phase 3 schizophrenia trials recruiting: 24 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials in phase 3 for schizophrenia that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 schizophrenia trials: 24 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/schizophrenia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 24
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 5, 2026 | NCT07918222 | Sequential Treatment Approaches for Treatment-Resistant Schizophrenia | Shanghai Mental Health Center | Phase 3 | Recruiting | Treatment-resistant Schizophrenia | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918222) |
| November 3, 2026 | NCT07911787 | Phase 3 Study of HS-10380 for Acute Schizophrenia in Chinese Adults | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | SCHIZOPHRENIA 1 (Disorder) | 476 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911787) |
| August 18, 2026 | NCT07770282 | Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome | All India Institute of Medical Sciences, Bhubaneswar | Phase 3 | Not yet recruiting | Schizophrenia Disorder, Metabolic Syndrome, Antipsychotic-induced Weight Gain, Cardiovascular Risk, Insulin Resistance | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770282) |
| August 12, 2026 | NCT07759869 | A Study to Evaluate the Long-term Safety of HS-10380 in Patients With Schizophrenia | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | SCHIZOPHRENIA 1 (Disorder) | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07759869) |
| July 7, 2026 | NCT07686263 | Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Recruiting | Schizophrenia | 472 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07686263) |
| February 20, 2026 | NCT07424404 | A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in... | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Recruiting | Schizophrenia, Autism-Related Irritability | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424404) |
| January 27, 2026 | NCT07369154 | 52-week Open Label Safety-Tolerability Study | LB Pharmaceuticals Inc. | Phase 3 | Recruiting | Schizophrenia | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07369154) |
| January 23, 2026 | NCT07363577 | Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia | LB Pharmaceuticals Inc. | Phase 3 | Recruiting | Schizophrenia | 456 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07363577) |
| December 17, 2025 | NCT07288567 | A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN) | Bristol-Myers Squibb | Phase 3 | Recruiting | Schizophrenia | 166 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07288567) |
| December 4, 2025 | NCT07263022 | Cognitive Strategies in Early Psychosis 2 | University of Minnesota | Phase 3 | Recruiting | Psychosis, Schizophrenia Disorder, Schizoaffective Disorder, Major Depressive Disorder With Psychotic Features, Bipolar... | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07263022) |
| November 13, 2025 | NCT07227818 | Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia | Neurocrine Biosciences | Phase 3 | Recruiting | Schizophrenia | 560 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07227818) |
| November 10, 2025 | NCT07225712 | A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia | Otsuka Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Schizophrenia | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225712) |
| September 22, 2025 | NCT07184619 | Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | Newron Pharmaceuticals SPA | Phase 3 | Recruiting | Treatment-resistant Schizophrenia | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07184619) |
| August 11, 2025 | NCT07114874 | NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia | Neurocrine Biosciences | Phase 3 | Recruiting | Schizophrenia | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07114874) |
| August 5, 2025 | NCT07105098 | NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | Neurocrine Biosciences | Phase 3 | Recruiting | Schizophrenia | 284 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07105098) |
| July 1, 2025 | NCT07045142 | Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients | Central South University | Phase 3 | Recruiting | Schizophrenia | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07045142) |
| May 8, 2025 | NCT06963034 | NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | Neurocrine Biosciences | Phase 3 | Recruiting | Schizophrenia | 284 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06963034) |
| May 8, 2025 | NCT06961968 | Randomized Withdrawal Study in Patients With Schizophrenia | Vanda Pharmaceuticals | Phase 3 | Recruiting | Schizophrenia | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06961968) |
| March 19, 2025 | NCT06882785 | A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia | Bristol-Myers Squibb | Phase 3 | Recruiting | Schizophrenia | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06882785) |
| July 1, 2024 | NCT06482554 | Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | Louisiana State University Health Sciences Center Shreveport | Phase 3 | Recruiting | Apathy, Schizophrenia, Schizophrenia; Psychosis | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06482554) |
| January 29, 2024 | NCT06229210 | Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder | Intra-Cellular Therapies, Inc. | Phase 3 | Recruiting | Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06229210) |
| March 31, 2022 | NCT05303064 | Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder | Alkermes, Inc. | Phase 3 | Recruiting | Schizophrenia, Bipolar I Disorder | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05303064) |
| January 11, 2022 | NCT05184335 | Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia | Reviva Pharmaceuticals | Phase 3 | Recruiting | Schizophrenia | 690 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05184335) |
| January 25, 2019 | NCT03817502 | Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | Gedeon Richter Plc. | Phase 3 | Recruiting | Schizophrenia | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03817502) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Neurocrine Biosciences](https://specstream.ai/data/clinical-trials/company/neurocrine-biosciences) | 4 |
| [Karuna Therapeutics, Inc., a Bristol Myers Squibb company](https://specstream.ai/data/clinical-trials/company/karuna-therapeutics-inc-a-bristol-myers-squibb-company) | 2 |
| LB Pharmaceuticals Inc. | 2 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 2 |
| [Jiangsu Hansoh Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hansoh-pharmaceutical-co-ltd) | 2 |
| All India Institute of Medical Sciences, Bhubaneswar | 1 |
| [Alkermes, Inc.](https://specstream.ai/data/clinical-trials/company/alkermes-inc) | 1 |
| [Intra-Cellular Therapies, Inc.](https://specstream.ai/data/clinical-trials/company/intra-cellular-therapies-inc) | 1 |
| Reviva Pharmaceuticals | 1 |
| Louisiana State University Health Sciences Center Shreveport | 1 |
| Shanghai Mental Health Center | 1 |
| [Vanda Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/vanda-pharmaceuticals) | 1 |
| Gedeon Richter Plc. | 1 |
| Central South University | 1 |
| University of Minnesota | 1 |
| [Otsuka Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/otsuka-pharmaceutical-co-ltd) | 1 |
| [Newron Pharmaceuticals SPA](https://specstream.ai/data/clinical-trials/company/newron-pharmaceuticals-spa) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 17 |
| Romania | 6 |
| Colombia | 5 |
| Serbia | 5 |
| Japan | 4 |
| China | 4 |
| Bulgaria | 4 |
| Puerto Rico | 3 |
| Argentina | 3 |
| Hungary | 2 |
| India | 2 |
| Poland | 2 |
| Spain | 2 |
| Mexico | 2 |
| Australia | 1 |
| Canada | 1 |
| France | 1 |
| Brazil | 1 |
| Russia | 1 |
| Ukraine | 1 |
| Czechia | 1 |
| Malaysia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Demolition contractors in the United States](https://specstream.ai/data/businesses/demolition-contractors/united-states)
- [Immigration law firms in the United States](https://specstream.ai/data/businesses/immigration-law-firms/united-states)
- [Physical therapy clinics in the United States](https://specstream.ai/data/businesses/physical-therapy-clinics/united-states)
- [Trucking companies in the United States](https://specstream.ai/data/businesses/trucking-companies/united-states)
- [Broadcast media production companies in the United States](https://specstream.ai/data/businesses/broadcast-media-production-companies/united-states)
- [Fertility clinics in the United States](https://specstream.ai/data/businesses/fertility-clinics/united-states)
